Objective: Around 50% of depressed patients do not respond to antidepressants. Evidence from familial studies suggests a genetic component to this. This study investigated whether patients with polymorphisms in genes related to the hypothalamic-pituitary-adrenal (HPA) axis were less likely to respond to antidepressants. Method: EMBASE, MEDLINE, PsycINFO, and the Cochrane Library were searched. Inclusionary criteria were: 1) patients with depression, 2) study of HPA axis-related candidate genes, 3) at least four weeks of antidepressants, and 4) assessment of depressive symptoms dividing patients into non-responders and responders. Results: Nineteen studies were identified. Non-responders and responders did not differ in single nucleotide polymorphisms (SNPs) in genes encoding arginine vasopressin. Findings were equivocal regarding genes encoding the FK506 binding protein 5 and glucocorticoid and mineralocorticoid receptors. Specific SNPs and haplotypes within genes related to corticotropin-releasing hormone (CRHBP, CRHR1) and melanocortins (POMC) predicted non-responder status. Conclusions: Replication studies and additional investigations exploring gene x environment and drug x environment interactions are necessary before pharmacological treatments may be adjusted based on a patient's genetic profile.
Introduction
Antidepressants are among the most widely used first-line treatments for patients with depressive disorders; however, around 50% of patients are not sufficiently responsive . This raises the question of the mechanisms underlying the non-response phenomenon.
Alterations in the stress-responsive hypothalamic-pituitary-adrenal (HPA) axis represent one of the most consistent pathophysiological findings in depressive disorders. They include elevated levels of corticotropin-releasing hormone (CRH; Waters et al., 2015) , elevated levels of adrenocorticotropic hormone (ACTH) and cortisol (Stetler and Miller, 2011) , reduced glucocorticoid sensitivity (Rohleder et al., 2010) , and mineralocorticoid to glucocorticoid receptor imbalance (de Kloet et al., 2007) . As for potential origins of these alterations, candidate-gene association studies have shown that polymorphisms in a number of genes related to HPA axis functioning appear to be more frequent in some patients with depressive disorders (Cohen-Woods et al., 2013; Ising and Holsboer, 2006) . Among these genes are: AVPR1A, coding for an arginine vasopressin (AVP) receptor; CRH, CRHBP, CRHR1 and CRHR2, coding for CRH, its binding protein and its receptors, respectively; POMC, involved in the synthesis of proopiomelanocortin, a precursor of ACTH; FKBP5, coding for the FK506-binding protein 5, a co-chaperone of glucocorticoid signalling; and NR3C1, a gene coding for the glucocorticoid receptor.
Evidence from meta-analysis suggests that alterations in the HPA axis are related to antidepressant treatment response (Fischer et al., 2017a) . Higher cortisol concentrations in particular appear to be linked with non-responses, although only in studies with a particular methodological profile. Given parallel evidence for a familial predisposition towards non-responses to antidepressants (Franchini et al., 1998) , the aim of the present study was to investigate whether non-responders to antidepressant treatment can be distinguished from responders by means of genetic HPA axis markers. Based on a previous meta-analysis https://doi.org/10.1016/j.neubiorev.2018.11.009 Received 10 June 2018; Received in revised form 10 September 2018; Accepted 18 November 2018
Screening and study selection
Identified records were screened according to the following inclusionary criteria: 1) adults with a current depressive disorder (i.e., major depressive disorder or persistent depressive disorder) diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders (DSM) or the International Classification of Diseases (ICD), 2) a candidate-gene study of at least one HPA axis-related gene (i.e., AVP, AVPR1A, AVPR1B, CRH, CRHR1, CRHR2, CRHBP, FKBP5, MC1R, NR3C1, NR3C2, POMC) , and 3) treatment including at least four weeks of continuous administration of antidepressants (i.e., monoamine oxidase (MAO) inhibitors, tri-or tetracyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), noradrenaline reuptake inhibitors, serotonin-noradrenaline reuptake inhibitors (SNRIs), noradrenaline-dopamine reuptake inhibitors, serotonin-noradrenalin-dopamine reuptake inhibitors), and 4) including a standardised measure of depressive symptoms dividing patients into non-responders and responders or non-remitters and remitters. Studies including bipolar patients were excluded. Comorbidity with somatic diseases, other mental disorders, intake of any medication upon study entry, and intake of medication pro re nata during the study were permitted, but recorded (see risk of bias assessment below). Studies that used more than one class of antidepressants were included, but again, this was noted. Fulltext articles were retrieved and checked for relevant results. All article reference sections were reviewed for additional records of potential relevance.
Extraction of study results
For each retrieved study, information was collected about the sample size, eligibility criteria (e.g., medication use), diagnostic procedures, determination of HPA axis-related polymorphisms, blinding, antidepressant treatment, response and remission rates, and main findings. Risk of bias was estimated by means of a modified version of a quality assessment scale that was used in previous meta-analyses on HPA axis functioning as a predictor of treatment response (see Table 1 ; Fischer and Cleare, 2017; Fischer et al., 2017a, b) . Seven items were scored on a three-point scale (0-2). The maximum attainable score was thus 14.
Results

Search results
The search yielded 29,893 records, of which 56 were considered of potential interest based on their title or abstract. Of these, 37 were excluded because they were not original research articles (e.g., book chapters), were not conducted in adults, included patients with bipolar disorder, were not candidate-gene studies of HPA axis-related genes, did not administer antidepressants, administered antidepressants for less than four weeks, used augmentation strategies, were retrospective in nature (e.g., cross-sectional comparison of genetic HPA axis-related polymorphisms in patients labelled "treatment resistant" vs. healthy controls), or did not contain results in terms of either treatment nonresponders versus responders or non-remitters versus remitters. In the end, N = 19 studies were eligible to be included in the systematic review.
Study characteristics
The main characteristics of the 19 included studies are shown in Tables 1-5. All were published between 2007 and 2015. The sample sizes ranged from 96 to 1719. Almost all patients fulfilled criteria for a major depressive disorder. Virtually no study reported on the prevalence of symptomatic subtypes. In total, 84% of studies excluded comorbidity with major mental disorders, 74% excluded medication intake at study entry, 53% excluded patients with some degree of previous treatment-resistance, and 42% excluded patients with major physical diseases. Polymorphisms in HPA axis genes were determined by means of different commercially available assays. Citalopram and fluoxetine were the most widely used antidepressants (6 studies each, equalling 64%), followed by escitalopram (4 studies, 21%). Antidepressants were administered from 4 to 14 weeks. The average response rate across studies was 60%, ranging from 43% to 72% (mostly assessed by the Hamilton Rating Scale for Depression; HAMD). The average remission rate was 50%, ranging from 38% to 69%.
Risk of bias
Quality ratings ranged from 2 to 9, with an average of 6 points (14 points maximum). The highest scores were achieved regarding the inclusionary and exclusionary criteria, which in general tended to be quite restrictive (item 1). Similarly, depressive disorders were diagnosed by clinical psychologists and psychiatrists rather than by students in most cases (item 2). Genetic marker selection, population stratification, minor allele frequencies and information on the HardyWeinberg equilibrium were reported by the majority of studies, whereas less than half reported information regarding assay reliability or models of penetrance (item 3). Antidepressant dosage was appropriate in more than half of the studies (item 4). By contrast, several studies failed to report whether response assessors were blind to polymorphisms (item 6) and statistical analyses were rarely fully adequate (item 7): A power analysis was undertaken in only six studies, only five studies controlled for age and sex, four for intake of medication pro re nata during treatment, and two for baseline symptom severity. Most studies did, however, adjust their results for multiple testing. No study used both clinician-rated and self-reported instruments to assess treatment response (item 5).
Polymorphisms in genes related to the arginine vasopressin (AVP) system
Three studies looked at polymorphisms in genes related to the AVP system (see Table 1 ). They were conducted in Chinese, Chilean, African American, European American, and Hispanic patients. A number of SNPs within AVP, AVPR1A, and AVPR1B were determined and patients Table 1 Characteristics of identified studies on polymorphisms in genes related to the arginine vasopressin (AVP) system and response to antidepressant treatment. (continued on next page)
were treated with different SSRIs and SNRIs for up to 12 weeks. None of the studies found any link between any of these SNPs and treatment response or remission.
Polymorphisms in genes related to the corticotropin-releasing hormone (CRH) system
Nine studies investigated polymorphisms in genes related to the CRH system (see Table 2 ). Three of these focused on CRH. These studies included patients of African American, European American, Hispanic, or Mexican American ethnicity. There was no link whatsoever between any SNPs and haplotypes located in CRH and response or remission after up to 12 weeks of treatment with tricyclic antidepressants, tetracyclic antidepressants, or SSRIs.
Three studies investigated CRHBP, coding for the CRH binding protein, in relation to treatment response. Binder et al. (2010) found that African American and Hispanic patients with a particular allele of a SNP in CRHBP (rs10473984) had a nearly two-fold higher probability of being a non-responder or non-remitter after up to 12 weeks of treatment with citalopram.
Six studies focused on CRHR1, coding for one of the CRH receptors. Geng et al. (2014) in their sample of Chinese patients found one SNP (rs28364032) and three related haplotypes in CRHR1 to be associated with an up to seven-fold increased risk of non-remission after 8 weeks of treatment with different SSRIs and SNRIs.
Finally, six studies looked at CRHR2, coding for another CRH receptor. Wong et al. (2008) found one SNP in CRHR2 (rs917195) to differ between Mexican American non-responders and responders undergoing 8 weeks of treatment with desipramine, while this did not apply to patients treated with 8 weeks of fluoxetine. Notably, this result was not adjusted for multiple testing. Tiwari et al. (2013) found another SNP in CRHR2 (rs1076292) to differ between African, European, and Hispanic non-responders and responders to up to 12 weeks of treatment with bupropion. However, this only applied to patients completing treatment and no such association was found with remission status.
Polymorphisms in genes related to the melanocortin system
Three studies looked at polymorphisms related to the melanocortin system (see Table 3 ). Two studies analysed POMC, coding for a precursor of ACTH. Chang et al. (2015b) found one haplotype comprising four SNPs within POMC to be linked with an up to six-fold increased risk of being a non-remitter after 8 weeks of treatment with escitalopram or mirtazapine. Wu et al. (2011) was the only study investigating polymorphisms in MC1R, coding for one of the melanocortin receptors. In their sample of Mexican American patients, two SNPs (rs2228478, rs2228479) differed between non-remitters and remitters after 8 weeks of treatment with desipramine, but not fluoxetine. However, no correction for multiple testing was applied, rendering this a tentative finding.
Polymorphisms in the gene coding for the FK506 binding protein 5
Ten studies investigated FKBP5 (see Table 4 ). In a mixed sample of patients with Black and White ethnicities, Lekman et al. (2008) found one SNP (rs4713916) located in FKBP5 to distinguish between nonremitters and remitters to up to 14 weeks of treatment with citalopram; it did not, however, distinguish non-responders from responders. Ellsworth et al. (2013) 
Polymorphisms in genes coding for the glucocorticoid and mineralocorticoid receptor
Nine studies investigated polymorphisms related to the glucocorticoid and mineralocorticoid receptor (see Table 5 ). Eight studies sequenced NR3C1, coding for the glucocorticoid receptor. In their study of Japanese patients, Takahashi et al. (2014) found one SNP (rs41423247) in NR3C1 to differ between non-responders and responders to 6 weeks of fluvoxamine treatment, while it failed to differ between non-remitters and remitters. No differences whatsoever were found for the subgroup of their patients undergoing 6 weeks of milnacipran treatment. Geng et al. (2014) did not find the same SNP to distinguish between Chinese non-responders and responders to 8 weeks of SSRI or SNRI treatment. Similarly, Ventura-Junca et al. (2014) could not replicate the positive finding in their Chilean sample undergoing 8 weeks of fluoxetine treatment, and neither could Lee et al. (2009) in a Korean sample of patients who were treated with citalopram for 8 weeks. Paddock et al. (2007) was the only study to sequence NR3C2, coding for the mineralocorticoid receptor. This was a sample of patients with Black or White ethnicity and no significant associations between SNPs in NR3C2 and responder or remitter status after 6 weeks of administering citalopram were reported.
Discussion
The systematic review yielded three main findings (see also Table 6 for a summary). First, genes coding for the CRH and melanocortin systems appear to contain a number of SNPs and haplotypes, which are able to predict antidepressant response in depressed patients. Second, findings related to genes coding for FKBP5 and the glucocorticoid and mineralocorticoid receptors are equivocal. Finally, there was a considerable risk of bias, which was mainly due to missing detail on how candidate-gene studies were conducted, a lack of a priori power analyses and statistical adjustment for relevant confounders, and failure to report blinding procedures.
The first finding of this systematic review is that certain SNPs and haplotypes within CRHBP, CRHR1, and POMC are powerful predictors of antidepressant response. Binder et al. (2010) found a specific SNP (rs10473984) located in CRHBP to distinguish between non-responders and responders to citalopram. This finding was recently extended by O'Connell et al. (2018) , who found another SNP (rs28365143) within CRHBP to predict responses to escitalopram and sertraline. Importantly, in the Binder et al. study, the same allele predicting non-response was also linked with greater serum ACTH concentrations. In addition, Geng et al. (2014) found a SNP (rs28364032) and related haplotypes within CRHR1 to predict remission after administering various SSRIs and SNRIs, and Chang et al. (2015b) found a haplotype within POMC to predict remission status after treatment with escitalopram or mirtazapine. Notably, studies reporting positive findings in terms of the CRH and melanocortin system had a much higher average quality score (7.3 out of 14) when compared to those reporting null-findings (4.5 out of 14), which highlights the need for further research adhering to high standards. When taken together, these findings resonate well with evidence of enhanced CRH (Waters et al., 2015) and ACTH (Stetler and Miller, 2011) levels in some patients with depressive disorders; however, not all functional links between these SNPs and HPA axis parameters have yet been established. Evidence for causative effects of these polymorphisms is warranted to increase our knowledge on how exactly genetic variance may affect antidepressant treatment.
The second finding of this systematic review purports that although pharmacogenetic studies focused on FKBP5 and NR3C1 are manifold, results are far from conclusive. In terms of FKBP5, Lekman et al. (2008) found a particular SNP (rs4713916) to predict remission status after administering citalopram. This aligns well with the fact that the same SNP resides within a functional region of FKBP5, implying causative links with FKBP5 protein expression (Zou et al., 2010) . However, three more recent studies included in the present systematic review were unable to replicate this finding (Ellsworth et al., 2013; Geng et al., 2014; Perlis et al., 2009 ). While two of these studies (Geng et al., 2014; Perlis et al., 2009) Equally conflicting findings were revealed regarding NR3C1. Takahashi et al. (2014) found that the Bcl1 polymorphism (rs41423247) separated Japanese non-responders and responders when they received fluvoxamine, while there was no apparent effect on response rates when patients received milnacipran. Three studies investigating the same SNP were unable to replicate this finding (Geng et al., 2014; Lee et al., 2009; Ventura-Junca et al., 2014) and again, ethnic diversity is a likely candidate in explaining these inconsistent findings. Further attempts at replicating the positive findings by Lekman et al. (2008) and Takahashi et al. (2014) in ethnically homogenous samples are thus imperative. Should the above findings be replicated, it is conceivable for depressed patients with a specific, HPA axis-related genetic predisposition to be less likely to respond to first-line treatments, such as antidepressants. The most likely mechanism translating these variants into non-responses is via measurable alterations in the HPA axis. Indeed, some studies have been successful in linking pre-treatment cortisol concentrations with antidepressant response (Fischer et al., 2017a) . In addition, antidepressants have repeatedly been demonstrated to normalise HPA axis functioning (Holsboer, 2000) , presumably via modulating glucocorticoid receptor functioning (Anacker et al., 2011) . In addition, interactions of the HPA axis with other stress-responsive systems, such as the immune system, may modulate treatment response (Strawbridge et al., 2015) , and a more comprehensive account of pretreatment alterations in stress-responsive bodily systems may thus be necessary to understand the mechanisms contributing to non-responses. However, this would imply a functional role of these polymorphisms in HPA axis functioning, and evidence for this is lacking for several of the SNPs identified in this systematic review.
Importantly, the genetic variance within HPA axis-related genes is unlikely to exert its potential influence on treatment response in isolation. Instead, there is a high probability for gene-environment interactions to occur. Some of the included studies have considered this by stratifying patients according to the presence of stressful life events (Chang et al., 2015a, b; Geng et al., 2014) . Indeed, Chang et al.'s (2015b) finding of a haplotype within POMC to predict non-remission was mainly driven by the subgroup of patients not reporting any stressful life events within the year preceding the current major depressive episode. This aligns well with more recent efforts exploring epigenetic modifications as predictors and modulators of treatment response (Belzeaux et al., 2018) . In contrast, Geng et al. (2014) found neither childhood trauma nor stressful life events within the past year to interact with a specific SNP within CRHR1 to predict remitter status. Further studies may be well-advised to include detailed histories of stressful experiences across the lifespan, and to complement genetic with epigenetic markers of the HPA axis. Related to this, drug-environment interactions should be considered by future research. This is important given that recent data suggest that the effect of antidepressants and psychoactive substances in general are co-determined by environmental factors, such as socioeconomic status or pre-treatment psychological state (Carhart-Harris et al., 2018; Chiarotti et al., 2017) . This is the first systematic review of HPA axis-related polymorphisms and antidepressant treatment response. Strengths of this study include the comprehensive literature search, the fact that we defined a distinct phenotype in terms of treatment response (non-responder vs. responder status), and our rigorous risk of bias assessment. On the other hand, relatively few studies matching our eligibility criteria were identified and a number of methodological issues became apparent during the risk of bias assessment. More specifically, the reporting of SNP assay performance and penetrance models, the use of an adequate dosage of antidepressants, the conducting of an a priori power analysis and adjustment for important confounders was insufficient in several of the included studies. This points to potential reasons for some of the null-findings as reported above, and it is thus strongly recommended that future studies are more vigilant in terms of these issues. Finally, due to the heterogeneity of the included studies it was not possible to integrate findings in a quantitative manner. Further research investigating the same SNPs and haplotypes identified in this review is warranted before a meaningful meta-analysis can be undertaken. In sum, this systematic review has identified a number of HPA axisrelated SNPs that hold the promise of identifying non-responders to antidepressant treatments. The current state of literature suggests that some of these are located within genes coding for the CRH and melanocortin systems, while the role of polymorphisms within FKBP5 and NR3C1 remains ambiguous. Further large-scale studies including additional HPA axis markers (e.g., DNA methylation, gene expression) and stratifying patients according to their current and past levels of stress and other environmental factors are necessary before additional or alternative treatments should be preferentially considered based on a patient's genetic profile.
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